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ABSTRACT
Objective: This study was undertaken to determine plasma and pelvic tissue concentrations of
piperacillin/tazobactam following a single intravenous administration.
Methods: Plasma and tissue samples were obtained following administration of 3 g of piperacillin
and {).375 g of tazobactam. Concentrations of these agents were determined by chromatography.
Results: Plasma concentrations (mean SD) for piperacillin/tazobactam were 208 _
87/27 _+ 8
and 95 -+ 53/14 + 2, respectively, at 30 and 60 min after the start of the infusion. The 8:1 ratio
between piperacillin and tazobactam in plasma remained constant for up to 96 min. Tissue concen-
trations yielded a broader range, but each agent achieved significant penetration in each of the
tissues studied.
Conclusions: Piperacillin/tazobactam demonstrates favorable penetration in female genital tract
tissues and should be considered a potentially effective agent for female pelvic infections.
(C) 1994 Wiley-Liss, Inc.
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he challenge of [3-1actamase-mediated antibiotic
resistance has led to the development of agents
with increasing resistance to enzymatic inactiva-
tion. When combined with these [3-1actamase in-
hibitors, antibiotics are effective against a broader
spectrum of organisms.
Currently available inhibitors include clavulanic
acid and sulbactam, which, in combination with
amoxicillin, ticarcillin, or ampicillin, have been
successful in treating infections caused by Staphylo-
coccus aureus, Bacteroids fragilis, Hemophilus influ-
enzae, Escherichia coli, and other gram-negative
baeteria. Tazobactam, a new derivative of penicil-
linic acid sulfone, acts as an irreversible inhibitor
of the [3-1actamase from many bacteria. Activity
has been demonstrated against plasmid-mediated
[3-1actamases and chromosome-encoded cephalos-
porinases produced by Enterobacteriaceae. In an
8:1 dosage ratio, the combination of piperacillin
and tazobactam has been markedly effective in the
treatment of a variety of infections.
2
An average of 2-4 aerobic and anaerobic organ-
isms can be isolated from women with postpartum
infection and endometritis.
3 Treatment is therefore
based on the polymicrobial nature of the disease. In
view of the varying clinical presentation and uncer-
tain microbial nature of female genital tract disease,
no agent with sufficiently certain efficacy is avail-
able. For this reason, a number of broad-spectrum
antibiotics and prophylaxis are often recom-
mended.
4
Several factors are important in selecting an an-
tibiotic for preoperative prophylaxis. The first con-
sideration is the activity of the agent against poten-
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tial pathogens. Surgical technique and duration of
procedure are contributing factors to the overall
efficacy. Another determinant is the tissue level
attained at the time of bacterial contamination, s
As an adjunct to safety and efficacy trials of the
combination of piperacillin and tazobactam, we un-
dertook a study to determine the penetration of
these agents into gynecologic organs in women
scheduled for hysterectomy.
SUBJECTS AND METHODS
Women in good general health who were scheduled
for elective hysterectomy were invited to participate
in the study. All of the women were 18 years of age
or older, weighed between 47.7 and 95.4 kg, and
gave full written informed consent approved by the
investigational review boards of the University of
South Florida and Tampa General Hospital.
Of36 potential subjects screened, 24 (67%) were
excluded or declined for the following reasons: can-
cellation of surgery (7); failure to meet inclusion
criteria (7); alteration of surgical approach (5); and
refusal of subject to volunteer (5). Twelve patients
were enrolled but 2 were excluded from analysis:
one patient inadvertently received an additional pre-
operative antibiotic and another was excluded be-
cause her samples had been stored at -20C for a
prolonged period of time.
Preoperative screening included medical history,
physical examination, chest X-ray, EKG, and labo-
ratory studies (CBC, BUN, total bilirubin, alka-
line phosphatase, SGPT, SGOT, creatinine, glu-
cose, uric acid, albumin, and urinalysis). Serum
samples were obtained and frozen at -70C should
the need for hepatitis screening arise.
Indications for surgery included leiomyomata (6
cases), endometriosis (2 cases), cervical dysplasia (1
case), and ovarian fibroma (1 case). Salpingo-
oophorectomy was performed in 8 of 10 cases and
these tissue samples were submitted for analysis.
Subjects ranged in height from 140 to 177 cm,
with a mean of 160.5 cm. Weights ranged between
47.7 and 95.4 kg, with a mean of 69.42 kg. Body
surface area ranged from 1.41 to 2.0 me, the mean
being 1.72 m2.
A single administration of 3 g of piperacillin and
0.375 g of tazobactam was delivered via infusion
pump over 30 min. The individual range for pip-
eracillin was 31.43-62.85 mg/kg and for tazobac-
tam was 3.93-7.86 mg/kg. The mean dose admin-
istered was 44.6 mg/kg of piperacillin in
combination with 5.57 mg/kg of tazobactam.
Antibiotic infusion began with induction of an-
esthesia; the average time from the initiation of
infusion to the time when circulation to the tissue
was interrupted was h. Blood samples were ob-
tained prior to drug administration and at the end
of the 30 min infusion. As the uterus, ovary, and
fallopian tubes were removed, the time was noted
and a blood sample was obtained within 5 min.
These were placed on ice until centrifuged, sepa-
rated into 2 equal aliquots, and stored at -70C.
Similarly, the tissue samples were trimmed of any
connective tissue, blotted clean, and weighed be-
fore storage. Uterine tissue was separated into en-
dometrial and myometrial components. All serum
and tissue samples were stored at -70C until ship-
ment in dry ice to the sponsor’s site for analysis.
Plasma and tissue concentrations were deter-
mined by modifications of established methods. 6’7
Separate high-performance liquid chromatographic
(HPLC) systems were used for the quantification
of each drug. Chromatographic separation of tissue
and plasma components was accomplished by re-
verse-phase separation columns, using column-
switching for quantification of tazobactam and
isocratic mobile-phase delivery systems for piper-
acillin. Conventional HPLC has never been sensi-
tive enough to measure [3-1actamase inhibitors at
concentrations less than 0.5 p,g/ml. Analysis of the
plasma samples included deproteinization with ace-
tonitrile and cefpodoxime as an internal standard.
After removal of the acetonitrile with dichlo-
romethane and centrifugation, the aqueous super-
natants were analyzed by HPLC using a column-
switching technique that allows a very sensitive and
precise measurement of tazobactam in plasma.
The tazobactam concentrations of 10 endome-
trial, 9 ovarian, and 8 fallopian tube samples were
measured. Tissue samples were thawed in ice wa-
ter. Adhesive blood was blotted away and any tissue
parts not identified as endometrium, myometrium,
ovary, or fallopian tube were removed. The sample
was then transferred to a 3.5 ml polystyrene test
tube and weighed on an analytical balance. The
weight was noted and the tissue was homogenized
in 2 volumes for not more than 10 sec by an ul-
traturrax homogenizer at 24 x 103 rpm. The re-
suiting homogenate was centrifuged for 10 min at
10 103 rpm, and 250 p,1 of supernatant was
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 21PENETRATION OF PIPERACILLIN/TAZOBACTAM O’BRIEN AND GEORGE
30
O
25-
o
o-
o
o
II 3O
25 >
N
O
2.0
O
-15
-5 r--
I1’ 0
30 60 90
TIME (MINUTES)
Fig. I. Plasma concentrations 30-90 min following infusion of 3 g of piperacillin and 0.375 g of
tazobactam (mean +- SEM).
deproteinized by the addition of 0.5 ml of acetoni-
trile containing the internal standard. The acetoni-
trile was removed by extraction with ml of dichlo-
romethane. After centrifugation at 10 103 rpm
for 10 min, 120 bl of the aqueous phase was in-
jected onto the HPLC system.
Chromatographic conditions for the mobile-
phase analysis were: for precolumn A, 0.1 M of
sodium dihydrogen phosphate and 5 mM of tet-
rabutylammonium hydrogen sulfate; for precolumn
B, acetonitrile, A/B: 95/5 (v:v), pH 6.5. The Li-
Chrosorb RP-2, 10 Im (40 4.6 mm I.D.), was
utilized. The flow rate was 1.0 ml/min and the
switching time was 6 min.
For analytical column A, 0.1 M ofsodium dihy-
drogen phosphate and 5 mM of tetrabutylammo-
nium hydrogen sulfate were used. For analytical
column B, acetonitrile, A/B: 9/1 (v:v), pH 6.5,
was used. The Spherisorb ODS II, 5
(250 4.6 mm I.D.), was utilized. The flow rate
was 1.5 ml/min.
For tazobactam, the retention time was 20-21
min and ultraviolet (UV) absorption was 210 nm.
For cefpodoxime, the retention time was 28-30
min and UV absorption was 300 nm. A water bath
temperature of25C was maintained. The injection
volume was 120 11.
Analysis of the tissue concentrations of piperacil-
lin includes centrifugation and deproteinization
with mezlocillin as the internal standard. Condi-
tions for piperacillin measurement were, with the
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Fig. 2. Tissue concentrations 30-60 min after infusion of 3
g of piperacillin and 0.375 g of tazobactam (median, 25-75
percentile).
mobile phase, column A, 0.1 M of potassium dihy-
drogen phosphate, and column B, acetonitrile, A/B:
4/1 (v:v), pH 5.5. The LiChrospher C 18, 5 Im
(250 4.6 mm I.D.), was utilized for the analyt-
ical column. The flow rate was 1.7 ml/min, the
injection volume was 40 pl, and the temperature of
the water bath was 37.5C. UV absorption was 220
nm for piperacillin and for mezlocillin.
Plasma samples were thawed, vigorously mixed,
and centrifuged for 5 min at 10 103 rpm. The
supernatant, 0.100 ml, was stabilized with 0.100
ml of 0.1 M potassium dihydrogen phosphate
buffer (pH 5.5) containing the internal standard.
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TABLE I. In vitro activity of piperacillin/tazobactam (8:1) vs. recent clinical isolates
Isolate No. MIC 50 MIC 90 Range
Escherichia coli 2309 2.5
Enterobacter aerogenes 175 5.2
E. cloacae 481 5.3
Klebsiella pneumoniae 650 1.6
K. oxytoca 223 3.7
Citrobacter diversus 112 2.
C. freundii 121 2.0
Serratia marcescens 338 6.4
Proteus mirabilis 545 0.6
P. vulgaris 70 0.7
Morganella morganii 144 I.
Providencia rettgeri 10 128
P. stuartii 31 2.5
Salmonella spp. 87 7.9
Shigella spp. 81 3.5
Pseudomonas aeruginosa 320 5.3
P. cepacia 21 10.4
Xanthomonas maltophilia 135 108.6
Acinetobacter spp. 354 19
Aeromonas spp. I0 2
Plesiomonas shigelloides 29 0.25
Branhamella catarrhalis 27 0.
Neisseria gonorrhoeae 16 0.3
N. meningitidis 10 0.3
Hemophilus influenzae 53 0.2
Staphylococcus aureus, oxa sensitive 168 3
S. aureus, oxa not specified 931 4
Staphylococcus coagulase negative, oxa sensitive 222 1.9
Staphylococcus coagulase negative, oxa not specified 814 2.9
Streptococcus pneumoniae 93 0.3
Enterococcus 525 3.8
Bacteroides fragilis 60 4
10.6 <0.5-256
29.3 <0.5-128
61.0 <0.5-> 128
17.3 <0.5-128
15.4 I-I 28
7.5 1-16
45.1 1-64
25.2 0.25-512
I. 0.12-64
1.3 0.25-64
9.9 <0.5-64
256 <0.5-> 128
10 0.25-32
49.2 0.12-16
47.4 0.12-16
57.4 0. I->256
14.5 <0.5-128
224 16-> 128
54.9 I->256
4 2-8
0.02-0.06
0.2 0.03-0.12
1.0 0.06-2
0.3 0.3-0.5
0.4 0.06-8
13.6 <0.5-128
8. I-4
3.9 <0.5-32
22.9 <0.5-128
0.5 0.03-1
8.5 50.5-6.4
16 <1-32
This solution was deproteinized by adding 0.400
ml of acetonitrile. After mixing and centrifugation
at 15 103 rpm, the acetonitrile was removed by
extraction with ml of dichloromethane. After
centrifugation at 10 103 rpm for 10 min, 0.040
ml of the aqueous phase was injected onto the
HPLC system.
RESULTS
Plasma samples were taken from 48 to 96 min
post-infusion, corresponding to the time tissues
were removed from circulation (Fig. 1). With one
exception, the 8:1 concentration ratio remained con-
stant in plasma for up to 96 min after administra-
tion. At 95 min, subject 7 had a BSA of 2.0 Me
and a plasma concentration ratio of 5.4.
At the time the tissues were removed from circu-
lation, approximately h after drug infusion, the
penetration of piperacillin into gynecological tis-
sues was 40-50% (Fig. 1). The range, 12.8-82.1
mcg/g, was sufficient to ensure antimicrobial ]3-1ac-
tamase activity. Tazobactam penetration was 60-
70%, ranging from 2.66 to 12.4 mcg/g. Anti-]3-
lactamase activity can be assured at these levels.
The range of concentration ratios was broader
for tissue samples than for plasma samples. En-
dometrial tissue had ratios ranging from 4.8 to
8.0, myometrial samples from 3.2 to 9.3, fallopian
tube samples from 3.8 to 6.9, and ovarian tissue
samples from 4.4 to 8.2 (Fig. 2).
DISCUSSION
Piperacillin/tazobactam is a recent addition to the
growing class of agents that combine broad-spec-
trum penicillin or cephalosporins with agents that
inhibit the activity of [3-1actamases. Clinical trials
have demonstrated a highly favorable response
in several types of infection. Most notably,
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piperacillin/tazobactam appears to be equally safe
and of superior efficacy when compared with
imipinem/cilastatin in the treatment of severe intra-
abdominal infections.
2 Optimal treatment of gyne-
cologic infections requires broad-spectrum antimi-
crobial activity in several tissues within the
reproductive tract. Tazobactam exhibits the highest
affinity for [3-1actamases of the currently available
inhibitor,s. When compared with amoxicillin-cla-
vulonate and ampicillin-sulbactam, piperacillin-
tazobactam shows the highest activity against [3-1ac-
tamase containing enteric gram-negative aerobes.
9
This antibacterial activity, however, must be
distributed throughout the tissues of the female
genital tract in order to effectively eradicate infec-
tion.
In this study, following a single infusion,
piperacillin/tazobactam retained an 8:1 ratio in
plasma samples obtained from 48 to 96 min follow-
ing infusion. This stability ofproportions was main-
tained at a moderately consistent level in the tissues
studied with a very favorable plasma to tissue ratio
of approximately 2:1. In vitro, these concentrations
result in effective inhibition against the organisms
expected in female genital tract infection (Table 1).
This high degree of penetration throughout the
tissues of the female genital tract, along with its
excellent penetration into areas of inflammation,
should result in a high degree of clinical efficacy in
the treatment of pelvic infections.
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